PDCD1 and neoplasm: The combination of NLRP3 inhibition by dapansutrile (OLT1177) and anti-PD-1 treatment significantly increased the antitumor efficacy by reducing MDSCs expansion and limiting MDSCs-mediated T-cell suppression and tumor progression (89).